News
-
-
PRESS RELEASE
Applied DNA Announces Pricing of $12 Million Public Offering
Applied DNA Sciences, Inc. announces pricing of public offering expected to raise $12.0 million. Offering includes Common Shares, Pre-Funded Warrants, Series A and Series B Warrants. Proceeds to support company's services and general purposes -
-
PRESS RELEASE
Institute of Hematology and Blood Transfusion (Prague) to Present on Successful Use of Applied DNA's Linea DNATM for the Non-Viral Manufacture of CAR T-Cell Therapy for Refractory AML
Applied DNA Sciences and IHBT announce abstract on enzyme-based CAR T-cell therapy manufacturing to be presented at EHA 2024 Congress. The study focuses on virus-free CD123-specific CAR T-cells using Linea DNA -
-
PRESS RELEASE
Applied DNA Announces Second Quarter Fiscal Year 2024 Financial Results
Applied DNA Sciences, Inc. announces Q2 fiscal 2024 financial results, reporting a decrease in revenues due to COVID-19 testing decline. Operating expenses decrease and loss from operations increases. Stock split completed and Nasdaq compliance regained -
-
-
-
